



Received on 02 June 2014; received in revised form, 12 August, 2014; accepted, 22 September, 2014; published 01 January, 2015

## A STUDY ON PREVALENCE OF POLYCYSTIC OVARY SYNDROME AT A TERTIARY CARE HOSPITAL

K. S. Lakshmi <sup>\*1</sup>, J. Jayasutha <sup>2</sup> and Anjalakshi Chandrasekar <sup>3</sup>

SRM College of Pharmacy <sup>1,2</sup>, SRM Medical College Hospital and Research Centre <sup>3</sup>, SRM University, Kancheepuram, Tamilnadu, India.

### Keywords:

Prevalence, Polycystic Ovary Syndrome, Hirsutism, Transabdominal Ultrasonography

### Correspondence to Author:

**K. S. Lakshmi**

Professor & Dean  
SRM College of Pharmacy,  
SRM University, Kancheepuram,  
Tamilnadu - 603203, India

E-mail: jayasutha15@gmail.com


**ABSTRACT:** The main objective of the study was to assess the prevalence of polycystic ovary syndrome at a tertiary care hospital. This study was a prospective observational study performed for a period of 6 months in infertility and gynecology clinic. For making a positive diagnosis of PCOS, all subjects were interviewed to furnish details of menstrual history including regularity, duration of cycles, and number of cycles per year or intermenstrual interval. Transabdominal ultrasonography and tests like Tests like fasting blood glucose, fasting insulin, follicle stimulating hormone (FSH), luteinizing hormone (LH), LH:FSH ratio and serum testosterone were performed. A total two hundred eight patients were attended infertility and gynecology clinic during the study period of six months, of which 67 (32%) patients were meeting the study criteria were included and assessed for the presence of polycystic ovary syndrome. Of the 67 patients, 57 patients experienced oligomenorrhea and remaining 10 patients had amenorrhea. 32 patients had hirsutism, 18 patients had acne and 4 patients had alopecia. Transabdominal ultrasonography showed the presence of polycystic ovaries in all 67 patients. Hence, the prevalence of PCOS at a tertiary care hospital was 32%.

**INTRODUCTION:** Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of reproductive age, affecting about 6.5–6.7% of all premenopausal women <sup>1, 2</sup>. The disorder originally described as cystic disease of the ovaries by Stein & Leventhal<sup>3</sup> is now considered to be associated with a barrage of endocrine and metabolic disturbances such as hypertension, impaired glucose tolerance (IGT), type 2 diabetes mellitus, coronary artery disease, increased risk of endometrial and perhaps breast cancer <sup>4</sup>.

The main endocrine derangements responsible for the clinical manifestations were hyperandrogenemia and abnormal insulin response to glucose <sup>5, 6</sup>. Insulin resistance (IR)/hyperinsulinemia in PCOS being the main pathogenic defect is also supported by clinical, biochemical, and hormonal response to insulin sensitizers<sup>7</sup>. Women with PCOS are at an increased risk for infertility, preeclampsia, early pregnancy loss, and endometrial cancer. Hence, the study has been conducted to assess the prevalence of PCOS at a tertiary care hospital.

### MATERIALS AND METHODS:

The study was a prospective observational study performed for a period of 6 months in infertility and gynecology clinic at SRM Medical College Hospital and Research Institute, Kancheepuram, Tamilnadu, India. Inclusion Criteria like women between 18 to 35 years of age with PCOS defined

QUICK RESPONSE CODE	DOI: 10.13040/IJPSR.0975-8232.6(1).383-85
	Article can be accessed online on: <a href="http://www.ijpsr.com">www.ijpsr.com</a>
DOI link: <a href="http://dx.doi.org/10.13040/IJPSR.0975-8232.6(1).383-85">http://dx.doi.org/10.13040/IJPSR.0975-8232.6(1).383-85</a>	

by Rotterdam criteria i) clinical and/or biochemical hyperandrogenism, ii) oligo-anovulation, and iii) polycystic ovaries on ultrasonography. Exclusion criteria like adrenal hyperplasia, thyroid dysfunction, hyperprolactinemia, cushing's syndrome, severe hepatic or kidney diseases.

The patients were enrolled into the study based on inclusion and exclusion criteria. Informed consent was obtained from the patient. Patients were subjected to detailed history, clinical examination, hormonal and ultrasonographic evaluation. For making a positive diagnosis of PCOS, all these subjects were interviewed to furnish details of menstrual history including regularity, duration of cycles, and number of cycles per year or intermenstrual interval.

The diagnosis of PCOS on transabdominal ultrasonography was based on the presence of 12 peripheral follicles each 2–9 mm in diameter in one or both ovaries, increased ovarian volume ( $10 \text{ cm}^3$ ) on one or both sides. Tests like fasting blood glucose, fasting insulin, free testosterone, follicle stimulating hormone (FSH), luteinizing hormone (LH), LH: FSH ratio and serum testosterone were performed on second day of the menstrual cycle and the statistical analysis was performed. Based on above parameters, the prevalence of PCOS was assessed.

## RESULTS AND DISCUSSION:

A total two hundred seven patients were attended infertility and gynecology clinic, of which 67 (32%) patients had PCOS. **Table 1** shows Mean±SD of various parameters. Of the 67 patients, 31 patients were in the age group of 18-25 years, 32 patients were in the age group of 26-30 years and 5 patients were in the age group of 31-35 years.

Majority of the patients included in the study were overweight and obese patients. Out of 67 patients, 57 patients experienced oligomenorrhea and remaining 10 patients had amenorrhea. Of this 67 patients, majority of the patients (32 patients) had hirsutism measured by Ferriman Gall way score which was  $\geq 7$ . 15 patients had acne and 4 patients had alopecia. Transabdominal ultrasonography showed the presence of polycystic ovaries in all 67

patients. The mean± SD of LH, FSH, LH: FSH and serum testosterone were  $12.2 \pm 4$ ,  $9 \pm 1.7$ ,  $1.3 \pm 0.6$  and  $2.8 \pm 0.7$ . From the result, it was clear that nearly 32% of women were suffered from PCOS. PCOS have a markedly increased risk of developing type 2 diabetes<sup>8,9</sup>.

Hence, it is important to treat PCOS. Heather R. Peppard concluded that PCOS occurs frequently among premenopausal women with type 2 diabetes<sup>10</sup>. Nidhi R et al proved that Prevalence of PCOS in Indian adolescents was 9.13%<sup>11</sup>.

**TABLE 1: SHOWS MEAN±SD OF VARIOUS PARAMETERS**

Parameters	Mean±SD (n=67)
Age	25±6
BMI (kg/m <sup>2</sup> )	28±7
Ferriman Gallway Score	12
LH (mIU/ml)	12.2±4
FSH (mIU/ml)	9±1.7
LH:FSH	1.3±0.6
Serum Testosterone (nmol/l)	2.8±0.7

Other studies on Asian population have reported lower prevalence rates: 6.3% in Sri Lankan population<sup>12</sup> and 2.4% in Chinese population. Higher prevalence in India as compared to other Asian countries could be expected because strong etiological link between PCOS and diabetes, and India has the higher prevalence of diabetes. Polycystic ovarian syndrome (PCOS) is the most common female endocrine disorder with a highly variable prevalence estimates, ranging from 2.2% to 26%<sup>13-17</sup>. March WA et al conducted a study on Australian population and showed a prevalence of 11.9%<sup>18</sup>.

**CONCLUSIONS:** From the result, it was clear that prevalence of PCOS at a tertiary care hospital was 32%. Hence, it is important to consider and treat PCOS in order to prevent the risk of developing type 2 diabetes, dyslipidemia, hypertension, and heart diseases.

**ACKNOWLEDGEMENTS:** We wish to place my heartfelt thanks to Dr. James Pandian, Dean, SRM Medical College Hospital & Research institute for his support.

**REFERENCES:**

1. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli C, Spina GG, Zapanti ED & Bartzis MI. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. *Journal of Clinical Endocrinology and Metabolism* 1999; 84:4006–4011.
2. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S & Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. *Journal of Clinical Endocrinology and Metabolism* 2000; 85: 2434–2438.
3. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. *American Journal of Obstetrics and Gynecology* 1935; 29: 181–191.
4. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. *Endocrine Reviews* 1997; 18: 774–800.
5. Goodarzi MO, Korenman SG. The importance of insulin resistance in polycystic ovary syndrome. *Fertility and Sterility* 2003; 80: 255–258.
6. Kulshreshtha B, Ganie MA, Praveen EP, Gupta N, Khurana ML, Seith A, Dwivedi SN, Kumar G & Ammini AC. Insulin response to oral glucose in healthy, lean young women and patients with polycystic ovary syndrome. *Gynecological Endocrinology* 2008; 24: 637–643.
7. Nieuwenhuis-Ruifrok AE, Kuchenbecker WK, Hoek A, Middleton P and Norman RJ. Insulin sensitizing drugs for weight loss in women of reproductive age who are overweight or obese: systematic review and meta-analysis. *Human Reproduction Update* 2009; 15: 57–68.
8. Ehrmann DA, Barnes RB, Rosenfeld RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. *Diabetes Care* 1999; 22:141-146.
9. Legro RS, Kunesman AR, Dodson WC, Dunaif A: Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women *J Clin Endocrinol Metab* 1999;84:165-169
10. Heather R. Peppard, Jennifer Marfori, Maria J. Iuorno, John E. Nestler. Prevalence of polycystic ovary syndrome among premenopausal women with type 2 diabetes. *Diabetes Care* 2001; 24(6):1050-1052.
11. Nidhi R, Padmalatha V, Nagarathna R, Amritanshu R. Prevalence of Polycystic Ovarian Syndrome in Indian Adolescents. *J Pediatr Adolesc Gynecol.* 2011;24:223–7
12. Kumarapeli V, Seneviratne R de A, Wijeyaratne CN, Yapa RM., Dodampahala SH. A simple screening approach for assessing community prevalence and phenotypes of polycystic ovary syndrome in semiurban population in Sri Lanka. *Am J Epidemiol* 2008;168:321-7
13. Chen X, Yang D, Mo Y, Li L, Chen Y, Huang Y. Prevalence of polycystic ovary syndrome in unselected women from southern China. *Eur J Obstet Gynecol Reprod Biol* 2008;139:59-64
14. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. *J Clin Endocrinol Metab* 2000;85:2434-8
15. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. *J Clin Endocrinol Metab* 2004;89:2745-9
16. Michelmores KF, Balen AH, Dunger DB, Vessey MP. Polycystic ovaries and associated clinical and biochemical features in young women. *Clin Endocrinol (Oxf)* 1999;51:779-86
17. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: Hormonal and metabolic profile. *J Clin Endocrinol Metab* 1999;84:4006-11
18. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. *Hum Reprod* 2010;25:544-51

**How to cite this article:**

Lakshmi KS, Jayasutha J and Chandrasekar A: A Study on Prevalence of Polycystic Ovary Syndrome at a Tertiary Care Hospital. *Int J Pharm Sci Res* 2015; 6(1): 383-85. doi: 10.13040/IJPSR.0975-8232.6 (1).383-85.

All © 2013 are reserved by International Journal of Pharmaceutical Sciences and Research. This Journal licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

This article can be downloaded to **ANDROID OS** based mobile. Scan QR Code using Code/Bar Scanner from your mobile. (Scanners are available on Google Playstore)